Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Schrödinger is trading near 52-week lows, prompting a fresh analysis. Learn more about SDGR stock and the complexities of its ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.

Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...